Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS

NCT07909460 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07909460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS
Lead sponsor
University College, London
Phase
Observational
Overall status
Not yet recruiting
Start date
January 4, 2027
Completion date
January 4, 2030
Enrollment
56 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 3 arms.

  • Glioma with epilepsy

    participants with glioma and tumour-related epilepsy.

  • Glioma without epilepsy

    participants with glioma who do not have epilepsy.

  • control group

    participants without glioma or epilepsy

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy. baseline

    inflammatory markers will be defined as blood brain barrier leakage using filter exchange imaging

Lead sponsor's other trials

University College, London, most recent start first.

Similar trials

Same condition (Epilepsy) and phase, most recent start first.